NAD+: Side Effects & Safety

NAD+ is a naturally occurring molecule present in every living cell — it is not a synthetic drug. Supplementation aims to restore levels that decline with age (approximately 50% decline between ages 40 and 60). The safety profile is generally favorable, with most adverse effects related to the route of administration rather than the molecule itself.

Oral NAD+ precursors (NMN, NR) have the most human safety data. Martens et al. (2018) demonstrated that NR supplementation was well-tolerated in healthy middle-aged and older adults, with no serious adverse events. Injectable NAD+ has less formal clinical trial safety data but has been used extensively in longevity clinics for years.

However, injectable NAD+ is notably more uncomfortable than most peptide injections, which is the primary practical concern for new users.

Injectable NAD+ (Subcutaneous)

Side Effect	Frequency	Severity	Management
Injection site stinging/burning	Very common	Moderate	Inject slowly, dilute solution, warm to room temp, ice site beforehand
Injection site redness	Common	Mild	Resolves within hours; rotate injection sites
Flushing/warmth	Occasional	Mild	More common at higher doses; transient (15-30 min)
Insomnia	Occasional	Mild-Moderate	Dose in the morning; avoid evening administration
Headache	Occasional	Mild	Usually transient; may relate to hydration status
Nausea	Rare	Mild	More common at higher doses; reduce dose if persistent

IV NAD+ Infusion

Side Effect	Frequency	Severity	Management
Chest tightness/pressure	Common	Moderate	Slow infusion rate; typically resolves within minutes of slowing
Nausea	Common	Mild-Moderate	Slow infusion rate; anti-nausea medication if needed
Flushing/sweating	Common	Mild	Related to rapid NAD+ increase; slowing infusion helps
Abdominal cramping	Occasional	Mild	Slow infusion; usually transient
Lightheadedness	Occasional	Mild	Ensure hydration; remain seated during infusion

Oral NMN/NR

Oral precursors have the mildest side effect profile. Reported effects are rare and typically include mild GI discomfort (nausea, bloating) at higher doses. Most clinical trials report tolerability equivalent to placebo.

Cancer Considerations

NAD+ is required by all rapidly dividing cells, including cancer cells. Cancer cells often upregulate NAD+ biosynthesis pathways to fuel their rapid proliferation. This raises a theoretical concern: could exogenous NAD+ supplementation fuel existing tumor growth?

• No clinical evidence has established that NAD+ supplementation causes or promotes cancer in humans
• Conversely, SIRT1 activation (which requires NAD+) has tumor-suppressive effects in some contexts, including p53 deacetylation and NF-κB suppression
• Some preclinical studies suggest NAMPT inhibition (reducing NAD+) as a cancer therapy strategy, implying that NAD+ repletion could theoretically counteract this approach
• Recommendation: NAD+ supplementation is generally considered contraindicated in individuals with active cancer until more definitive research is available. Consult an oncologist.

Drug Interactions

NAD+ metabolism intersects with several pharmaceutical pathways:

• Metformin: Both metformin and NAD+ influence AMPK and SIRT1 pathways. Some researchers suggest potential synergy, but combining without medical supervision is not recommended
• Chemotherapy: Some chemotherapy agents work by depleting cancer cell NAD+ (NAMPT inhibitors). NAD+ supplementation could theoretically reduce chemotherapy efficacy
• Immunosuppressants: NAD+ influences immune cell function through CD38 and sirtuin pathways. Potential interactions with immunomodulatory medications exist

Long-Term Data Gaps

• NR has the most long-term human safety data (1-2 year studies published), showing good tolerability
• Long-term safety of high-dose injectable NAD+ (500+ mg daily for years) is not established from controlled trials
• The theoretical concern about supraphysiological NAD+ levels — whether chronically elevated NAD+ could have unintended consequences — remains under investigation

Practical strategies to reduce NAD+ side effects:

• For injection pain: Use a more dilute reconstitution (lower mg/mL concentration), inject very slowly (15-30 seconds), warm the syringe to room temperature before injecting, and consider icing the injection site for 30 seconds before injection
• For insomnia: Strictly administer in the morning. Avoid any NAD+ supplementation after 2 PM
• For flushing: Start at a lower dose and titrate up over 1-2 weeks. Stay well-hydrated
• For IV-related effects: Work with an experienced clinic that can adjust infusion rates in real-time. Standard infusions take 1-3 hours; faster rates increase side effects
• General: Start at the lowest dose (50-100 mg injectable, 250 mg oral) and increase gradually. Get baseline bloodwork including a metabolic panel

• Active cancer — theoretical concern regarding NAD+'s role in cellular proliferation (consult oncologist)
• Undergoing chemotherapy — potential interference with NAMPT-inhibiting chemotherapy agents
• Uncontrolled cardiovascular conditions — transient hemodynamic effects during IV infusion warrant caution
• Pregnancy and breastfeeding — insufficient safety data for high-dose supplementation
• Children under 18 — NAD+ levels are naturally high in youth; supplementation has not been studied in pediatric populations

Return to the NAD+ overview for general information, or see Are Peptides Safe? for broader peptide safety context.